Twenty-five institutions collaborate with Cofactor to validate OncoPrism for use in head and neck cancer patients ..read more

In response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma ..read more

NEW YORK – After announcing a collaboration with Intermountain Health spinout Culmination Bio earlier this week, Cofactor Genomics is “moving aggressively” to advance its OncoPrism test for predicting whether patients with a range of cancers are likely to benefit from immunotherapy ..read more

A familiar refrain for those who have traveled on London’s tube, “mind the gap” is a warning to take caution while crossing between the station platform and the train door. In oncology, patients and clinicians have been minding their own gap — the precision-medicine gap — for decades.  For decades, travelers on the London Underground have heard the brief but impactful phrase “Mind the Gap” broadcast over a loudspeaker as the train approaches and passengers enter or exit the cars. The gap — a physical distance between the curved tracks and the platform — was deemed unsafe but unavoidable ..read more

How macromolecules and machine learning can work together to expand the frontiers of precision medicine Most stories have a hero and a villain – but we don’t often see the same character take on both roles. You may have chosen to forget Superman II (and possibly Superman III), but I am sure COVID-19 is still very fresh in your mind. In this sickening plot, RNA plays a villain – a coronavirus that challenged our immune systems and wreaked havoc around the world. But the best stories have a twist, and RNA has also become a hero – taking the form of mRNA vaccines that allow our immune ..read more

Culmination Bio, a new Intermountain Health Company, and Cofactor Genomics, a predictive diagnostic immunotherapy company, today announced a partnership to leverage samples and data from one of the largest biobanks in the country to fuel the development of Cofactor Genomic’s OncoPrism test in 11 cancers ..read more

This collection highlights our most downloaded cancer papers published in 2022. Featuring authors from around the world, these papers showcase valuable research from an international community ..read more

SAN FRANCISCO–(BUSINESS WIRE)–Cofactor Genomics, the diagnostics company bridging the precision medicine gap, today announced commencement of a study of its OncoPrism assay in non-small cell lung cancer (NSCLC), the second indication being studied in the company’s national PREDAPT study that will ultimately encompass 11 cancers. OncoPrism is the company’s diagnostic platform that generates multidimensional immune biomarkers using Predictive Immune Modeling. This approach has been shown to predict immunotherapy responders with twice the accuracy of on-market PD-L1 assays, with the added benefit ..read more

Jarret Glasscock, PhD, CEO of Cofactor Genomics explains how diagnostics are emerging as the key to ensuring the right patients get matched to the right therapy, at the right time.  Precision medicine promises a paradigm shift to confidently match the right patients to the right treatment at the right time. In pursuit of this, the number of new therapeutics in development has boomed. In the cancer space alone over the last five years, clinical trials have increased 500% for new drugs and new drug combinations. New classes of therapies have added to this growth, including immune checkpoin ..read more

Readout from the national PREDAPT multicenter clinical trial presented at AGBT Precision Health Conference Cofactor Genomics, a Predictive Immune Modeling company, today presented initial results from the PREDAPT (Predicting Immunotherapy Efficacy From Analysis of Pre-treatment Tumor Biopsies) multicenter clinical trial at this week’s Advances in Genome Biology and Technology Precision Health Meeting. Data show that Cofactor’s OncoPrism test using Predictive Immune Modeling was nearly twice as accurate as PD-L1 assays in determining patients that will benefit from immunotherapies such as Keytr ..read more